267 related articles for article (PubMed ID: 34989724)
1. Radiotherapy for glioblastoma: clinical issues and nanotechnology strategies.
Li R; Wang H; Liang Q; Chen L; Ren J
Biomater Sci; 2022 Feb; 10(4):892-908. PubMed ID: 34989724
[TBL] [Abstract][Full Text] [Related]
2. Novel Strategies for Nanoparticle-Based Radiosensitization in Glioblastoma.
Ruiz-Garcia H; Ramirez-Loera C; Malouff TD; Seneviratne DS; Palmer JD; Trifiletti DM
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575840
[TBL] [Abstract][Full Text] [Related]
3. Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme.
Choi J; Kim G; Cho SB; Im HJ
J Nanobiotechnology; 2020 Sep; 18(1):122. PubMed ID: 32883290
[TBL] [Abstract][Full Text] [Related]
4. MSI1 associates glioblastoma radioresistance via homologous recombination repair, tumor invasion and cancer stem-like cell properties.
Lin JC; Tsai JT; Chao TY; Ma HI; Chien CS; Liu WH
Radiother Oncol; 2018 Nov; 129(2):352-363. PubMed ID: 30322656
[TBL] [Abstract][Full Text] [Related]
5. Deregulated MicroRNA Signature Following Glioblastoma Irradiation.
Toraih EA; El-Wazir A; Abdallah HY; Tantawy MA; Fawzy MS
Cancer Control; 2019; 26(1):1073274819847226. PubMed ID: 31046428
[TBL] [Abstract][Full Text] [Related]
6. Advances in drug delivery technology for the treatment of glioblastoma multiforme.
Cha GD; Kang T; Baik S; Kim D; Choi SH; Hyeon T; Kim DH
J Control Release; 2020 Dec; 328():350-367. PubMed ID: 32896613
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Radioresponse and Radiosensitizers in Glioblastoma Organotypic Cultures.
Bayin NS; Ma L; Placantonakis DG; Barcellos-Hoff MH
Methods Mol Biol; 2018; 1741():171-182. PubMed ID: 29392699
[TBL] [Abstract][Full Text] [Related]
8. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment
Yang J; Shi Z; Liu R; Wu Y; Zhang X
Theranostics; 2020; 10(7):3223-3239. PubMed ID: 32194864
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme.
Chang JE; Khuntia D; Robins HI; Mehta MP
Clin Adv Hematol Oncol; 2007 Nov; 5(11):894-902, 907-15. PubMed ID: 18185489
[TBL] [Abstract][Full Text] [Related]
10. Drug delivery approaches for the treatment of glioblastoma multiforme.
Fakhoury M
Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
[TBL] [Abstract][Full Text] [Related]
11. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers.
Delello Di Filippo L; Hofstätter Azambuja J; Paes Dutra JA; Tavares Luiz M; Lobato Duarte J; Nicoleti LR; Olalla Saad ST; Chorilli M
Eur J Pharm Biopharm; 2021 Nov; 168():76-89. PubMed ID: 34461214
[TBL] [Abstract][Full Text] [Related]
12. Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: A nanotechnological approach.
Agarwal S; Muniyandi P; Maekawa T; Kumar DS
Int J Pharm; 2018 Nov; 551(1-2):339-361. PubMed ID: 30236647
[TBL] [Abstract][Full Text] [Related]
13. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
[TBL] [Abstract][Full Text] [Related]
14. CD44-associated radioresistance of glioblastoma in irradiated brain areas with optimal tumor coverage.
Liu WH; Lin JC; Chou YC; Li MH; Tsai JT
Cancer Med; 2020 Jan; 9(1):350-360. PubMed ID: 31746135
[TBL] [Abstract][Full Text] [Related]
15. GBM radiosensitizers: dead in the water…or just the beginning?
Bindra RS; Chalmers AJ; Evans S; Dewhirst M
J Neurooncol; 2017 Sep; 134(3):513-521. PubMed ID: 28762004
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis.
Yang YP; Chang YL; Huang PI; Chiou GY; Tseng LM; Chiou SH; Chen MH; Chen MT; Shih YH; Chang CH; Hsu CC; Ma HI; Wang CT; Tsai LL; Yu CC; Chang CJ
J Cell Physiol; 2012 Mar; 227(3):976-93. PubMed ID: 21503893
[TBL] [Abstract][Full Text] [Related]
17. The use of radiosensitizing agents in the therapy of glioblastoma multiforme-a comprehensive review.
Pepper NB; Stummer W; Eich HT
Strahlenther Onkol; 2022 Jun; 198(6):507-526. PubMed ID: 35503461
[TBL] [Abstract][Full Text] [Related]
18. Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma.
Degorre C; Tofilon P; Camphausen K; Mathen P
Radiat Oncol; 2021 Sep; 16(1):191. PubMed ID: 34583727
[TBL] [Abstract][Full Text] [Related]
19. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma.
Geng L; Shinohara ET; Kim D; Tan J; Osusky K; Shyr Y; Hallahan DE
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):263-71. PubMed ID: 16274936
[TBL] [Abstract][Full Text] [Related]
20. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
